Your browser doesn't support javascript.
loading
Feasibility and acceptability of patient- and clinician-level antithrombotic stewardship interventions to reduce gastrointestinal bleeding risk in patients using warfarin (Anticoagulation with Enhanced Gastrointestinal Safety): a factorial randomized controlled pilot trial.
Kurlander, Jacob E; Helminski, Danielle; Yuan, Liyang; Krein, Sarah L; Lanham, Michael S M; Henstock, Jennifer L; Kidwell, Kelley M; De Vries, Raymond; Resnicow, Kenneth; Sholl, Haden; Kim, Joyce J; Perry, Linda K; Parsons, Jacqueline; Ha, Nghi; Froehlich, James B; Aikens, James E; Richardson, Caroline R; Saini, Sameer D; Barnes, Geoffrey D.
Afiliação
  • Kurlander JE; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Helminski D; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, USA.
  • Yuan L; Veterans Affairs Ann Arbor Center for Clinical Management Research, Ann Arbor, Michigan, USA.
  • Krein SL; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Lanham MSM; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
  • Henstock JL; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Kidwell KM; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, USA.
  • De Vries R; Veterans Affairs Ann Arbor Center for Clinical Management Research, Ann Arbor, Michigan, USA.
  • Resnicow K; Department of Learning Health Sciences, University of Michigan, Ann Arbor, Michigan, USA.
  • Sholl H; Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, USA.
  • Kim JJ; University of Michigan Office of Clinical Informatics, Ann Arbor, Michigan, USA.
  • Perry LK; Health Information Technology and Services, University of Michigan, Ann Arbor, Michigan, USA.
  • Parsons J; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
  • Ha N; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, USA.
  • Froehlich JB; Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, USA.
  • Aikens JE; Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Richardson CR; Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
  • Saini SD; University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, USA.
  • Barnes GD; Department of Medicine, Division of General Internal Medicine, Vanderbilt University, Nashville, Tennessee, USA.
Res Pract Thromb Haemost ; 8(4): 102421, 2024 May.
Article em En | MEDLINE | ID: mdl-38827255
ABSTRACT

Background:

Overuse of antiplatelet therapy and underuse of gastroprotection contribute to preventable bleeding in patients taking anticoagulants.

Objectives:

(1) Determine the feasibility of a factorial trial testing patient activation and clinician outreach to reduce gastrointestinal (GI) bleeding risk in patients prescribed warfarin-antiplatelet therapy without proton pump inhibitor gastroprotection and (2) assess intervention acceptability.

Methods:

Pragmatic 2 × 2 factorial cluster-randomized controlled pilot comparing (1) a patient activation booklet vs usual care and (2) clinician notification vs clinician notification plus nurse facilitation was performed. The primary feasibility outcome was percentage of patients completing a structured telephone assessment after 5 weeks. Exploratory outcomes, including effectiveness, were evaluated using chart review, surveys, and semistructured interviews.

Results:

Among 47 eligible patients, 35/47 (74.5%; 95% CI, 58.6%-85.7%) met the feasibility outcome. In the subset confirmed to be high risk for upper GI bleeding, 11/29 (37.9%; 95% CI, 16.9%-64.7%) made a medication change, without differences between intervention arms. In interviews, few patients reported reviewing the activation booklet; barriers included underestimating GI bleeding risk, misunderstanding the booklet's purpose, and receiving excessive health communication materials. Clinicians responded to notification messages for 24/47 patients (51.1%; 95% CI, 26.4%-75.4%), which was lower for surgeons than nonsurgeons (22.7% vs 76.0%). Medical specialists but not surgeons viewed clinician notification as acceptable.

Conclusion:

The proposed trial design and outcome ascertainment strategy were feasible, but the patient activation intervention is unlikely to be effective as designed. While clinician notification appears promising, it may not be acceptable to surgeons, findings which support further refinement and testing of a clinician notification intervention.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Res Pract Thromb Haemost Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Res Pract Thromb Haemost Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos